These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34155803)

  • 21. New Perspectives on Development of Curative Strategies for Chronic Hepatitis B.
    Feld JJ; Lok AS; Zoulim F
    Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2040-2050. PubMed ID: 37080262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome].
    Moucari R; Marcellin P
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 2():S119-25. PubMed ID: 21095515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
    Yang YC; Yang HC
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Will we need novel combinations to cure HBV infection?
    Dusheiko G
    Liver Int; 2020 Feb; 40 Suppl 1():35-42. PubMed ID: 32077595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New strategies for the treatment of chronic hepatitis B.
    Mak LY; Cheung KS; Fung J; Seto WK; Yuen MF
    Trends Mol Med; 2022 Sep; 28(9):742-757. PubMed ID: 35780008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection.
    Wu S; Yi W; Gao Y; Deng W; Bi X; Lin Y; Yang L; Lu Y; Liu R; Chang M; Shen G; Hu L; Zhang L; Li M; Xie Y
    Front Immunol; 2022; 13():893512. PubMed ID: 35634301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
    Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
    Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
    Cho YK; Song BC
    Korean J Gastroenterol; 2011 Mar; 57(3):144-9. PubMed ID: 21519161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels.
    Zhang Q; Liu X; Pang X; Wang H; Du J; Ren H; Hu P
    Cytokine; 2023 Apr; 164():156140. PubMed ID: 36738524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Delaugerre C; Danel C; Zoulim F; Lacombe K;
    J Viral Hepat; 2018 Oct; 25(10):1121-1131. PubMed ID: 29660214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A 2020 update on the progress of treatment and new drug clinical trials for hepatitis B].
    Jia JD; Niu JQ; You H; Kong YY; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):97-101. PubMed ID: 33685074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
    Baugh SDP
    Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
    Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
    Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future anti-HBV strategies.
    Gane EJ
    Liver Int; 2017 Jan; 37 Suppl 1():40-44. PubMed ID: 28052637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure.
    Tsounis EP; Tourkochristou E; Mouzaki A; Triantos C
    World J Gastroenterol; 2021 Jun; 27(21):2727-2757. PubMed ID: 34135551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. State-of-the-art and emerging antivirals for chronic hepatitis B infection.
    Papatheodoridi M; Papatheodoridis GV
    Expert Opin Pharmacother; 2022 Dec; 23(18):1999-2012. PubMed ID: 36329612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.